[Low-dose testosterone undecanoate capsules combined with tadalafil for late-onset hypogonadism accompanied with ED].
OBJECTIVE
To observe the clinical effect of low-dose testosterone undecanoate capsules combined with tadalafil on late-onset hypogonadism (LOH) accompanied with ED.


METHODS
Ninety cases of LOH accompanied with ED who met the inclusion criteria were randomly divided into a control group and a combination therapy group, the former treated with tadalafil and the latter with low-dose testosterone undecanoate capsules combined with tadalafil. The LOH symptoms, IIEF-5 scores, sexual encounter profile (SEP) scores, prostate volumes, and the levels of total testosterone (TT), free testosterone (FT) and prostatic specific antigen (PSA) were recorded and compared between the two groups before and after treatment.


RESULTS
The IIEF-5 and SEP scores and the TT and FT levels were 20.6 +/- 3.8, 4.02 +/- 1.08, (15.4 +/- 3.4) nmol/L and (0.391 +/- 0.062) nmol/L, respectively, in the combination therapy group after treatment, significantly higher both than 15.7 +/- 3.9, 1.49 +/- 0.82, (10.1 +/- 1.2) nmol/L and (0.200 +/- 0.045) nmol/L before treatment (P < 0.01) and than 8.6 +/- 3.6, 3.50 +/- 1.21, (10.2 +/- 1.2) nmol/L and (0.210 +/- 0.051) nmol/L in the control group after treatment (P < 0.01).


CONCLUSIONS
Low-dose testosterone undecanoate capsules combined with tadalafil has a definite clinical effect and no obvious adverse reactions in the treatment of LOH accompanied with ED.
Department of Andrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China. gy7705@126.com
Guang-Yu
GY
Li
Ji-Hong
JH
Liang
Zhi-Bin
ZB
Meng
Cun-Chao
CC
Huang
Shi-Kun
SK
Liang
Guo-Qiang
GQ
Wei
Shu-Lin
SL
Shen
Chun-Hui
CH
Zhu
Xun
X
Zhang
Wei-Ru
WR
Song
D000328:Adult; D002243:Carbolines / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007006:Hypogonadism / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000068581:Tadalafil; D013739:Testosterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D002243:Carbolines; D013739:Testosterone; D000068581:Tadalafil; C010792:testosterone undecanoate